This is a routine board appointment with no immediate financial catalyst. Monitor for future announcements regarding regulatory milestones or partnership discussions that Ms. Kalter's expertise may support.
Price Chart
Executive Summary
Autonomix Medical appointed Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic, as an independent board member, expanding the board from five to six members. Ms. Kalter brings over four decades of MedTech regulatory and M&A experience, including oversight of more than 27 acquisitions at Medtronic. This is a routine board appointment with no financial terms disclosed, providing strategic regulatory expertise as the company advances its nerve-sensing platform toward clinical development.
Key Facts
- Board expanded from five to six members with the appointment of Sandra Cohen Kalter as an independent director.
- Ms. Kalter served as Vice President and Chief Regulatory Counsel at Medtronic from May 2011 to January 2025.
- She oversaw due diligence and integration for more than 27 acquisitions at Medtronic.
- Ms. Kalter will participate in the company's standard compensation program for non-employee directors.
- No committees have been assigned to Ms. Kalter at this time.
Financial Impact
No financial impact; standard non-employee director compensation not disclosed.
Risk Factors
- No material risks identified from this filing; the company's technology remains investigational and not yet cleared for marketing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030505 |
| Exhibit: ex_1016420.htm | 0001437749-26-030505 |
| Document: 0001437749-26-030505-index-headers.html | 0001437749-26-030505 |
| Document: 0001437749-26-030505-index.html | 0001437749-26-030505 |
| Document: 0001437749-26-030505.txt | 0001437749-26-030505 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $3.01 | awaiting T+20 | — | $2.42 (−19.60%) |
Oct 2, 2026 24d ago | Press Release | $3.78 | awaiting T+20 | — | $2.42 (−35.98%) |
Sep 16, 2026 5w ago | 8-K | $4.12 $3.01 | ▼ −26.94% | ▼ −30.12% | $2.42 (−41.26%) |
Sep 16, 2026 5w ago | EFFECT | $4.12 $3.01 | ▲ +26.94% | ▲ +30.12% | $2.42 (+41.26%) |
Sep 11, 2026 6w ago | 424B5 | $4.33 $3.10 | ▲ +28.41% | ▲ +30.67% | $2.42 (+44.11%) |
Sep 4, 2026 7w ago | S-3 | $4.58 $3.47 | ▲ +24.24% | ▲ +25.95% | $2.42 (+47.16%) |
Aug 26, 2026 8w ago | 8-K | $5.63 $4.07 | ▼ −27.71% | ▼ −27.20% | $2.42 (−57.02%) |
Aug 5, 2026 11w ago | EFFECT | $12.10 $4.50 | ▼ −62.81% | ▼ −62.21% | $2.42 (−80.00%) |
Jul 28, 2026 12w ago | 8-K | $2.75 $7.19 | ▲ +161.45% | ▲ +158.07% | $2.42 (−12.00%) |
Jul 15, 2026 14w ago | 8-K | $4.92 $6.86 | ▼ −39.43% | ▼ −35.81% | $2.42 (+50.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers